EGFR, VEGF, and HER2 in Cholangiocarcinoma
Author Information
Author(s): D. Yoshikawa, H. Ojima, M. Iwasaki, N. Hiraoka, T. Kosuge, S. Kasai, S. Hirohashi, T. Shibata
Primary Institution: National Cancer Center Research Institute, Tokyo, Japan
Hypothesis
The study investigates the clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
Conclusion
EGFR expression is associated with poor prognosis in intrahepatic cholangiocarcinoma, while VEGF expression may be involved in metastasis.
Supporting Evidence
- EGFR overexpression was associated with several poor prognostic factors in extrahepatic cholangiocarcinoma.
- VEGF expression was significantly associated with intrahepatic metastasis in intrahepatic cholangiocarcinoma.
- Multivariate analysis showed that EGFR expression is an independent prognostic factor.
Takeaway
This study looked at how certain proteins in cancer cells can help doctors understand how bad the cancer is and how to treat it better.
Methodology
Immunohistochemical expression of EGFR, VEGF, and HER2 was assessed in 236 cholangiocarcinoma cases, along with their associations with clinical outcomes.
Potential Biases
Potential biases in patient selection and retrospective data collection.
Limitations
The study is retrospective and may not account for all confounding factors.
Participant Demographics
236 patients (160 male, 76 female) with a median age of 65 years.
Statistical Information
P-Value
0.0006
Confidence Interval
1.52–4.69
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website